Epidemiology of Kaposi's sarcoma-associated herpesvirus in HIV-1-infected US persons in the era of combination antiretroviral therapy

AIDS

Volumn 29, Issue 10, 2015, Pages 1217-1225

  Labo, Nazzarena ^a,b   Miley, Wendell ^a   Benson, Constance A ^c   Campbell, Thomas B ^d   Whitby, Denise ^a  

^a FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Antiretroviral therapy; Epidemiology; Herpesvirus 8; Highly active; HIV 1; Human; Kaposi's sarcoma

Indexed keywords

ACICLOVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CIDOFOVIR; FAMCICLOVIR; FOSCARNET; GANCICLOVIR; VALACICLOVIR; VALGANCICLOVIR; ANTIRETROVIRUS AGENT; VIRUS ANTIBODY;

ADULT; AREA UNDER THE CURVE; ARTICLE; CAUCASIAN; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; FEMALE; GROUPS BY AGE; HERPES VIRUS INFECTION; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INCIDENCE; KAPOSI SARCOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NONHUMAN; OPEN READING FRAME; OVERALL SURVIVAL; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEX DIFFERENCE; UNITED STATES; VIRUS LOAD; BLOOD; COMPLICATION; CONTROLLED STUDY; HERPESVIRIDAE INFECTIONS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; IMMUNOLOGY; ISOLATION AND PURIFICATION; LONGITUDINAL STUDY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; VIROLOGY;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIBODIES, VIRAL; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; FEMALE; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 8, HUMAN; HIV INFECTIONS; HIV-1; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SEROEPIDEMIOLOGIC STUDIES; UNITED STATES;

EID: 84942924849     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000682     Document Type: Article

References (38)

1. de Sanjose S, Mbisa G, Perez-Alvarez S, Benavente Y, Sukvirach S, Hieu NT, et al. Geographic variation in the prevalence of Kaposi's sarcoma-Associated herpesvirus and risk factors for transmission. J Infect Dis 2009; 199:1449-1456.
2. Martin J. The epidemiology of KSHV and its association with malignant disease. In Arvin AGC-F, Mocarski E, Moore PS, Roizman B, Whitley R, Yamanishi K, editors. Herpesviruses: biology, therapy, and immunoprophylaxis. Cambridge: Cambridge University Press; 2007 [Chapter 54].
3. Martin JN, Ganem DE, Osmond DH, Page-Shafer KA, Macrae D, Kedes DH. Sexual transmission and the natural history of human herpesvirus 8 infection. N Engl J Med 1998; 338:948-954.
4. Goudsmit J, Renwick N, Dukers NH, Coutinho RA, Heisterkamp S, Bakker M, et al. Human herpesvirus 8 infections in the Amsterdam Cohort Studies (1984-1997): analysis of seroconversions to ORF65 and ORF73. Proc Natl Acad Sci U S A 2000; 97:4838-4843.
5. Melbye M, Cook PM, Hjalgrim H, Begtrup K, Simpson GR, Biggar RJ, et al. Risk factors for Kaposi's-sarcoma-Associated herpesvirus (KSHV/HHV-8) seropositivity in a cohort of homosexual men, 1981-1996. Int J Cancer 1998; 77:543-548.
6. Sullivan RJ, Pantanowitz L, Casper C, Stebbing J, Dezube BJ. HIV/AIDS: epidemiology, pathophysiology, and treatment of Kaposi sarcoma-Associated herpesvirus disease: Kaposi sarcoma, primary effusion lymphoma, and multicentric Castleman disease. Clin Infect Dis 2008; 47:1209-1215.
7. Jones JL, Hanson DL, Dworkin MS, Jaffe HW. Incidence and trends in Kaposi's sarcoma in the era of effective antiretroviral therapy. J Acquir Immune Defic Syndr 2000; 24:270-274.
8. Schwarcz L, Chen MJ, Vittinghoff E, Hsu L, Schwarcz S. Declining incidence of AIDS-defining opportunistic illnesses: results from 16 years of population-based AIDS surveillance. AIDS 2013; 27:597-605.
9. Jacobson LP, Yamashita TE, Detels R, Margolick JB, Chmiel JS, Kingsley LA, et al. Impact of potent antiretroviral therapy on the incidence of Kaposi's sarcoma and non-Hodgkin's lymphomas among HIV-1-infected individuals. Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr 1999; 21 (Suppl 1): S34-S41.
10. Veugelers PJ, Strathdee SA, Moss AR, Page KA, Tindall B, Schechter MT, et al. Is the human immunodeficiency virusrelated Kaposi's sarcoma epidemic coming to an end? Insights from the Tricontinental Seroconverter Study. Epidemiology 1995; 6:382-386.
11. Engels EA, Biggar RJ, Hall HI, Cross H, Crutchfield A, Finch JL, et al. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer 2008; 123:187-194.
12. Hleyhel M, Belot A, Bouvier AM, Tattevin P, Pacanowski J, Genet P, et al. Risk of AIDS-defining cancers among HIV-1-infected patients in France between 1992 and 2009: results from the FHDH-ANRS CO4 cohort. Clin Infect Dis 2013; 57:1638-1647.
13. Robbins HA, Pfeiffer RM, Shiels MS, Li J, Hall HI, Engels EA. Excess cancers among HIV-infected people in the United States. J Natl Cancer Inst 2015; 107:dju503.
14. Maurer T, Ponte M, Leslie K. HIV-Associated Kaposi's sarcoma with a high CD4 count and a low viral load. N Engl J Med 2007; 357:1352-1353.
15. Mani D, Neil N, Israel R, Aboulafia DM. A retrospective analysis of AIDS-Associated Kaposi's sarcoma in patients with undetectable HIV viral loads and CD4 counts greater than 300 cells/mm(3). J Int Assoc Physicians AIDS Care (Chic) 2009; 8:279-285.
16. Unemori P, Leslie KS, Hunt PW, Sinclair E, Epling L, Mitsuyasu R, et al. Immunosenescence is associated with presence of Kaposi's sarcoma in antiretroviral treated HIV infection. AIDS 2013; 27:1735-1742.
17. Stebbing J, Powles T, Bower M. AIDS-Associated Kaposi's sarcoma associated with a low viral load and a high CD4 cell count. AIDS 2008; 22:551-552.
18. Gnann JW Jr., Pellett PE, Jaffe HW. Human herpesvirus 8 and Kaposi's sarcoma in persons infected with human immunodeficiency virus. Clin Infect Dis 2000; 30 (Suppl 1):S72-S76.
19. Zhang X, Fitzpatrick L, Campbell TB, Badaro R, Schechter M, Melo M, et al. Comparison of the prevalence of antibodies to human herpesvirus 8 (Kaposi's sarcoma-Associated herpesvirus) in Brazil and Colorado. J Infect Dis 1998; 178:1488-1491.
20. Davis DA, Humphrey RW, Newcomb FM, O'Brien TR, Goedert JJ, Straus SE, et al. Detection of serum antibodies to a Kaposi's sarcoma-Associated herpesvirus-specific peptide. J Infect Dis 1997; 175:1071-1079.
21. Lennette ET, Blackbourn DJ, Levy JA. Antibodies to human herpesvirus type 8 in the general population and in Kaposi's sarcoma patients. Lancet 1996; 348:858-861.
22. Kedes DH, Ganem D, Ameli N, Bacchetti P, Greenblatt R. The prevalence of serum antibody to human herpesvirus 8 (Kaposi sarcoma-Associated herpesvirus) among HIV-seropositive and high-risk HIV-seronegative women. JAMA 1997; 277:478-481.
23. Smurzynski M, Collier AC, Koletar SL, Bosch RJ, Wu K, Bastow B, et al. AIDS clinical trials group longitudinal linked randomized trials (ALLRT): rationale, design, and baseline characteristics. HIV Clin Trials 2008; 9:269-282.
24. Mbisa GL, Miley W, Gamache CJ, Gillette WK, Esposito D, Hopkins R, et al. Detection of antibodies to Kaposi's sarcomaassociated herpesvirus: a new approach using K8.1 ELISA and a newly developed recombinant LANA ELISA. J Immunol Methods 2010; 356:39-46.
25. Quinlivan EB, Wang RX, Stewart PW, Kolmoltri C, Regamey N, Erb P, et al. Longitudinal sero-reactivity to human herpesvirus 8 (KSHV) in the Swiss HIV Cohort 4.7 years before KS. J Med Virol 2001; 64:157-166.
26. Biggar RJ, Engels EA, Whitby D, Kedes DH, Goedert JJ. Antibody reactivity to latent and lytic antigens to human herpesvirus-8 in longitudinally followed homosexual men. J Infect Dis 2003; 187:12-18.
27. Lieb S, Fallon SJ, Friedman SR, Thompson DR, Gates GJ, Liberti TM, et al. Statewide estimation of racial/ethnic populations of men who have sex with men in the U.S. Public Health Rep 2011; 126:60-72.
28. Beral V, Bull D, Jaffe H, Evans B, Gill N, Tillett H, et al. Is risk of Kaposi's sarcoma in AIDS patients in Britain increased if sexual partners came from United States or Africa Br Med J 1991; 302:624-625.
29. Armstrong AW, Lam KH, Chase EP. Epidemiology of classic and AIDS-related Kaposi's sarcoma in the USA: incidence, survival, and geographical distribution from 1975 to 2005. Epidemiol Infect 2013; 141:200-206.
30. Konopnicki D, Manigart Y, Gilles C, Barlow P, de Marchin J, Feoli F, et al. Sustained viral suppression and higher CD4R T-cell count reduces the risk of persistent cervical high-risk human papillomavirus infection in HIV-positive women. J Infect Dis 2013; 207:1723-1729.
31. Gantt S, Carlsson J, Ikoma M, Gachelet E, Gray M, Geballe AP, et al. The HIV protease inhibitor nelfinavir inhibits Kaposi's sarcoma-Associated herpesvirus replication in vitro. Antimicrob Agents Chemother 2011; 55:2696-2703.
32. Franceschi S, Lise M, Clifford GM, Rickenbach M, Levi F, Maspoli M, et al. Changing patterns of cancer incidence in the early-And late-HAART periods: the Swiss HIV Cohort Study. Br J Cancer 2010; 103:416-422.
33. Pipkin S, Scheer S, Okeigwe I, Schwarcz S, Harris DH, Hessol NA. The effect of HAART and calendar period on Kaposi's sarcoma and non-Hodgkin lymphoma: results of a match between an AIDS and cancer registry. AIDS 2011; 25:463-471.
34. Bohlius J, Valeri F, Maskew M, Prozesky H, Garone D, Sengayi M, et al. Kaposi's sarcoma in HIV-infected patients in South Africa: multicohort study in the antiretroviral therapy era. Int J Cancer 2014; 135:2644-2652.
35. Nelson BC, Borok MZ, Mhlanga TO, Makadzange AT, Campbell TB. AIDS-Associated Kaposi sarcoma: outcomes after initiation of antiretroviral therapy at a university-Affiliated hospital in urban Zimbabwe. Int J Infect Dis 2013; 17:e902-e906.
36. Chu KM, Mahlangeni G, Swannet S, Ford NP, Boulle A, Van Cutsem G. AIDS-Associated Kaposi's sarcoma is linked to advanced disease and high mortality in a primary care HIV programme in South Africa. J Int AIDS Soc 2010; 13:23.
37. Maskew M, Fox MP, van Cutsem G, Chu K, Macphail P, Boulle A, et al. Treatment response and mortality among patients starting antiretroviral therapy with and without Kaposi sarcoma: a cohort study. PLoS One 2013; 8:e64392.
38. Lodi S, Guiguet M, Costagliola D, Fisher M, de Luca A, Porter K, et al. Kaposi sarcoma incidence and survival among HIVinfected homosexual men after HIV seroconversion. J Natl Cancer Inst 2010; 102:784-792.